BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Business Wire India First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patients Study is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announc